Company Overview
Accuray Incorporated operates within the healthcare sector, specifically focusing on the medical devices industry, where it designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for tumor treatment across a global footprint that includes the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company maintains a workforce of 990 employees and holds a market capitalization of $46.99M, while reporting trailing twelve-month revenue of $436.97M. These financial figures indicate that Accuray is a mid-cap entity with a substantial revenue base relative to its valuation, suggesting a specialized position in a niche medical technology market. The disparity between the company's significant annual revenue of $436.97M and its modest market cap of $46.99M highlights a significant disconnect between current market valuation and the operational scale of the business, positioning the stock as a high-risk, high-potential-recovery asset based on current pricing metrics.
Financial Health
The company reported revenue of $436.97M over the trailing twelve months, yet recorded a net income of -$35,622,000 and an EBITDA of -$1,700,000, revealing a substantial gap between top-line generation and bottom-line profitability that points to a heavy cost structure or significant one-time expenses impacting the net income figure. This negative net income and negative EBITDA indicate that the company is currently burning cash operations-wise, which directly constrains its financial flexibility and ability to fund internal expansion without external capital injection. The company generated free cash flow of -$803,500, further confirming a cash-burning environment that requires careful capital management to avoid liquidity issues in the absence of new financing. Analyzing the margins reveals a gross margin of 27.8%, which suggests a moderate pricing power or cost advantage in manufacturing, contrasted by an operating margin of 3.7% and a profit margin of -8.2% that reflect the severe pressure on overall profitability. The balance sheet shows cash assets of $116.37M against total debt of $199.41M, resulting in a debt-to-equity ratio of 289.67, which characterizes the company as highly leveraged with obligations significantly exceeding its liquid cash reserves. Despite the high leverage, the current ratio stands at 1.47, indicating that the company possesses sufficient short-term liquid assets to cover its immediate liabilities, though not by a wide safety margin. Return on equity is reported at -70.3% and return on assets at -1.2%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is reported at -13.19, implying that the market currently prices in expected losses rather than earnings growth in the near term. The price-to-book ratio stands at 0.88, indicating that the market values the company at a discount to its book value, which is often a signal of distressed valuation or perceived high risk regarding future asset recovery. Alternative valuation metrics such as the price-to-sales ratio of 0.11 and the EV/EBITDA of -76.49 suggest that the stock is priced extremely low relative to its sales and enterprise value, reflecting a market consensus that current earnings power is negligible or negative. The stock has traded between a 52-week low of $0.33 and a 52-week high of $2.10, meaning the current price sits within a range that encompasses both significant downside volatility and recent recovery, though the exact current price is not provided to calculate a specific percentage below the high. The beta value of 1.20 indicates that the stock's price volatility is 20% higher than the broader market, suggesting that price movements will likely be amplified during periods of general market turbulence.
Growth & Income
Accuray Incorporated experienced a revenue growth of 16.8% year-over-year, while earnings growth is listed as N/A due to the negative earnings baseline, implying that top-line expansion is occurring even as the company struggles to turn operations profitable. Since the company is not a dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically available for reinvestment or debt repayment rather than distribution to shareholders. The absence of a dividend yield and the negative earnings growth profile indicate that the company is prioritizing operational survival and potential future growth over providing current income to investors. The overall growth and income profile is characterized by strong revenue expansion of 16.8% offset by negative earnings and a lack of dividend income, creating a scenario where capital appreciation is the only potential return source despite the high leverage and negative cash flow.